Harrington Discovery Institute Announces 2023 Scholar-Innovator Award Recipients
26 Apr 2023
10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic
CLEVELAND, April 26, 2023 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2023 class of Harrington Scholar-Innovators. The scholar awards will support a diverse set of projects including new breakthrough treatments for autoimmune disorders, cancer, heart failure, kidney disease, and severe forms of epilepsy.
Harrington Discovery Institute was established in 2012 to accelerate the development of new treatments to address major unmet needs in medicine and society. Harrington Scholar-Innovators are accomplished physician-scientists whose research demonstrates innovation, creativity and potential for clinical impact. In addition to grant funding, Harrington provides guidance and oversight in drug development, while intellectual property is retained by the scholar and their institution.
Since its founding, Harrington Discovery Institute has supported 165 drugs-in-the-making, 65 institutions, 36 company launches, 19 clinical candidates, and 13 licenses to pharma.
"Now in our second decade, we continue to be inspired by the brilliant science demonstrated in academic labs across the U.S. and Canada. It is an honor to support these extraordinary physician-scientists and their novel medicines-in-the-making that have the potential to significantly improve human health," said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University.
In addition to grant funding and tailored drug development guidance, Harrington Scholar-Innovators have the opportunity to access acceleration funds up to $300,000 and to qualify for mission-related investment funds typically up to $2 million. Scholars also have facilitated access to Harrington's mission-aligned commercial entities, the Advent-Harrington Impact Fund and BioMotiv, and to its charitable partner Morgan Stanley GIFT Cures.
The 2023 Harrington Scholar-Innovator Award recipients, their organizations and fields of research are:
Kirk Campbell, MD – Icahn School of Medicine at Mount Sinai
Novel therapeutics for proteinuric kidney disease
Jacques Galipeau, MD – University of Wisconsin, Madison
Curative treatment for type 1 diabetes
Won Jin Ho, MD – Johns Hopkins University
Novel treatment to enhance antitumor immunity
Maximillian Konig, MD – Johns Hopkins University
T-cell therapies for antiphospholipid syndrome, a rare autoimmune disorder
Berge Minassian, MD – UT Southwestern
New therapy for the fatal teenage-onset epilepsy, Lafora disease
Michael Pacold, MD, PhD – New York University
A drug for pancreatic cancer
Anthony Rosenzweig, MD – University of Michigan
Nucleic acid therapy for heart failure
Jeffrey Schelling, MD – Case Western Reserve University
Novel drug to treat diabetic kidney disease
Ming-Ru Wu, MD, PhD – Dana-Farber Cancer InstituteCancer Institute
Treating melanoma via the body's own immune system
Timothy Yu, MD, PhD – Boston Children's Hospital
Personalized therapies for epileptic encephalopathies
Harrington Discovery Institute is now accepting Letters of Intent for the
2024 Harrington Scholar-Innovator Award. The deadline to submit a brief Letter of Intent is
June 5, 2023. The full application deadline, for those invited to submit, is August 7, 2023. Learn more and apply to the 2024 Scholar-Innovator Award at HarringtonDiscovery.org/Scholar-Innovators.
SOURCE Harrington Discovery Institute
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.